Novartis M&A Strategy Faces Investor Scrutiny After Drug Setbacks 
Tabletop particle accelerator could transform medicine and materials science 
US-Backed Pediatric HIV Treatment Drops After Foreign Aid Changes, Study Finds 
Securitize, LG CNS Partner on South Korea Tokenization 
Gate Launches Gate Money as Crypto Super App Race Heats Up 
Novo Nordisk Strikes €1.17 Billion Nanexa Drug Delivery Deal 
Hengrui Shares Rise on $2.6 Billion Novo Nordisk Obesity Drug Deal 
Trump Plans Diesel Tax Relief as Fuel Prices Hit Record Highs 
World Bank Raises South Asia Growth Forecast to 6.9% 
Rapidus Seeks Chip Customers as Japan Pushes 2nm Semiconductor Revival 
NASA's Artemis II Crew Arrives in Florida for Historic Moon Mission 
Robinhood Buys $25 Million in Bitcoin for Corporate Treasury 
AstraZeneca Halts Phase III Volrustomig Lung Cancer Trial After Efficacy Setback 
FDA Weighs Safety Standards for Psychedelic Therapies 
Asian Currencies Steady as Dollar Holds Near 18-Month High 
Nomura Asset Management Targets Global Investors as Japan Markets Gain Appeal 
RBI Raises Repo Rate to 5.50% in Hawkish Shift on Inflation Risks 
Add as a preferred source on Google
Fujirebio Holding is now doubling down on developing blood tests to detect Alzheimer’s against which blockbuster therapy is expected soon.
The tiny Tokyo-based diagnostics firm, a unit of H.U. Group Holdings, which has a market value of $1.2 billion, developed the first US-approved spinal fluid test for Alzheimer’s.
According to Goki Ishikawa, the CEO of Fujirebio, the firm is boosting its lineup of reagents used to detect Alzheimer’s biomarkers in blood tests. It aims to file these tests for approval in the US as early as 2023.
Ishikawa said that the lineups offered by industry leaders are still limited, so they are rushing to create a solid lineup of tests.
